Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Net Sales at Rs 2.40 crore in December 2024 down 78.14% from Rs. 10.97 crore in December 2023. Quarterly Net Profit at Rs.

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

just as our beloved Omer showed until the very end,” Omer’s parents Ronen and Orna and brother Daniel say in a joint statement, expressing their gratitude for the support they have received ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...